Search results
Results From The WOW.Com Content Network
A drug combination chart designed for harm reduction by TripSit [1] Polysubstance use or multisubstance use is the use of combinations of psychoactive substances with both legal and illegal substances. This page lists polysubstance combinations that are entheogenic, recreational, or off-label indicated use of pharmaceuticals.
Dextromethorphan's effects have been divided into four plateaus. [14] The first plateau (1.5 to 2.5 mg per kg body weight) is described as having euphoria, auditory changes, mild stimulation, and change in perception of gravity. The second plateau (2.5 to 7.5 mg/kg) causes intense euphoria, vivid imagination, and closed-eye hallucinations.
Dextromethorphan/bupropion has less activity as an NMDA receptor antagonist than dextromethorphan alone. [11] This is because bupropion is a potent CYP2D6 inhibitor and prevents the bioactivation of dextromethorphan into dextrorphan , a much more potent NMDA receptor antagonist and weaker serotonin reuptake inhibitor than dextromethorphan ...
Dextromethorphan, sold under the brand name Robitussin among others, is a cough suppressant used in many cough and cold medicines. [6] In 2022, the US Food and Drug Administration (FDA) approved the combination dextromethorphan/bupropion to serve as a rapid-acting antidepressant in people with major depressive disorder.
Chart of drug dependence potential and relationship between use and lethal dose [33] Chart of relative harmfulness of some psychoactive substances [32] Drug harmfulness is defined as the degree to which a psychoactive drug has the potential to cause harm to the user and is measured in several ways, such as by addictiveness and the potential for ...
Marquis reagent was first discovered in 1896 [2] and described by the Russian (Estonian) pharmacologist, Eduard Markus (1871–1944) (Russian: Эдуард Маркус) [3] in his magister dissertation in 1896; [4] and named after him, [5] and was tested for the first time at the University of Dorpat.
Deudextromethorphan/quinidine (d-DXM/Q; developmental code names AVP-786, CTP-786) is a combination of deudextromethorphan (d-DXM; deuterated (d6) dextromethorphan (DXM)) and quinidine (Q) which is under development by Avanir Pharmaceuticals for the treatment of a variety of neurological and psychiatric indications.
dextromethorphan: Erectile dysfunction drugs: sildenafil (Viagra) tadalafil (Cialis) vardenafil (Levitra) HIV protease inhibitors: saquinavir (Invirase) ritonavir (Norvir) nelfinavir (Viracept) amprenavir (Agenerase) Hormones: ethinylestradiol (Ortho-Cept, many others) methylprednisolone (Medrol) Immunosuppressants: ciclosporin (Sandimmune ...